CARGO Therapeutics Announces Pricing of Initial Public Offering
November 09, 2023 20:07 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023 17:00 ET
|
Marker Therapeutics
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023 10:10 ET
|
ADC Therapeutics SA
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated...
Leukapheresis Market Research Report 2023 - Global Opportunity/Analysis to 2028
September 25, 2023 10:33 ET
|
Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma),...
Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research
September 14, 2023 09:51 ET
|
Emergen Research
Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...
ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in...
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023 19:33 ET
|
ADC Therapeutics SA
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in...
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 16:30 ET
|
Marker Therapeutics
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023 07:00 ET
|
ADC Therapeutics SA
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio...
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023 07:21 ET
|
ADC Therapeutics SA
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE:...